NH TherAguix announced the appointment of Vincent Carrère as Chief Executive Officer (CEO).
Events
NH TherAguix announces the release of a new clinical batch for it’s drug AGuIX manufactured by CARBOGEN AMCIS
MEYLAN, France, BUBENDORF, Switzerland (November 3rd, 2021) – NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.
NH TherAguix staff member awarded with a Ph.D. prize
NH TherAguix is pleased to announce that Fabien Boux which joined the Clinical Development Unit as Biomedical Engineer in January, was awarded with the Ph. D. prize 2020 of the Société Française de Résonance Magnétique en Biologie et Médecine (“SFRMBM”).